Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Notice of REVA Medical Briefing Call

Posted on: 07 Aug 17

SAN DIEGO, Aug. 07, 2017 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”) will hold a briefing call on Thursday, August 10, 2017 at 4:00 p.m. PDT (which is 9:00 a.m. AEST on Friday, 11 August 2017). Ms. Reggie Groves, the Company’s Chief Executive Officer, will host the call.

Ms. Groves will provide an update on REVA’s commercialization of the Fantom scaffold, as well as discuss the recent expiration of Boston Scientific Corporation’s option to negotiate distribution of the Company’s bioresorbable scaffold products.

As previously announced, REVA’s first commercial contract was signed with the Universitätsklinikum Schleswig-Holstein in Kiel, Germany. Dr. Matthias Lutz performed the first commercial procedure with Fantom at the hospital in July.  

“The results of the procedure were very positive and the patient is doing well,” said Dr. Lutz. “Bioresorbable scaffolds [BRS] allow us to treat coronary artery disease without the concerns of leaving behind a permanent implant. We look forward to continuing to offer BRS treatment with the Fantom scaffold to our patients.”

REVA’s briefing call can be accessed toll-free within Australia by dialing 1800 005 989 five minutes prior to the scheduled start time. Callers in the United States and Canada can access the call by dialing 1-877-312-5413. The conference ID number is 6592 5015 for all locations.

Callers outside of Australia, the United States, and Canada can access the call as an audiocast through our website at The link, “listen to webcast,” is provided in the “Events and Presentations” tab in the “Investors” section of the website. A recording of the audiocast will be available on the website after the call.

About REVA

REVA is a medical device company located in San Diego, California, USA, that has developed and commercialized a proprietary bioresorbable scaffold, as an alternative to metal stents, to treat coronary artery disease. Scaffolds provide restoration of blood flow, support the artery through the healing process, then disappear (or “resorb”) from the body over a period of time. This resorption allows the return of natural movement and function of the artery, a result not attainable with permanent metal stents. The Company’s Fantom® scaffold, which received European CE Marking on April 3, 2017, is designed to offer an ideal balance of thinness and strength, with distinct ease-of-use features including complete scaffold visibility under x-ray, expansion with one continuous inflation, and no procedural time limitations.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management. All statements that are not statements of historical fact, including those statements that address future operating performance and events or developments that we expect or anticipate will occur in the future, are forward-looking statements, such as those statements regarding our ability to commercialize current products, develop and commercialize new products, timely and successfully complete clinical trials, obtain additional regulatory approvals, protect our intellectual property position, recruit and retain key personnel, and estimates regarding our capital requirements and financial performance. Readers should not place undue reliance on forward-looking statements. Although management believes forward-looking statements are reasonable as and when made, forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to vary materially from those expressed in forward-looking statements, including the risks and uncertainties that are described in the "Risk Factors" section of our Annual Report on Form 10-K filed with the US Securities and Exchange Commission (the “SEC”) on February 28, 2017, and as updated in our periodic reports thereafter. Any forward-looking statements in this announcement speak only as of the date when made. REVA does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

CONTACT: United States Investor & Media Enquiries: REVA Medical, Inc. Cheryl Liberatore Director, Communications +1 858-966-3045 Australia Investor Enquiries: Inteq Limited Kim Jacobs +61 438 217 279 Andrew Cohen +61 408 333 452 Australia Media Enquiries: Buchan Consulting Rebecca Wilson +61 3 9866 4722 GlobeNewswire

Last updated on: 08/08/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.